CNPY3 and ovarian carcinoma: In this study, we pursued comprehensive molecular profiling of CNPY3 and GRP94 and found that both CNPY3 and GRP94 are upregulated in different human cancers, including breast, liver, colon, pancreatic, ovarian cancers, etc., suggesting that CNPY3 may be a potential biomarker and therapeutic target for pan cancers (Figures S1 and S2).